[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 633,194,368
  • Shares Outstanding, K 2,407,217
  • Annual Sales, $ 94,193 M
  • Annual Income, $ 26,804 M
  • EBIT $ 23,115 M
  • EBITDA $ 30,618 M
  • 60-Month Beta 0.24
  • Price/Sales 6.49
  • Price/Cash Flow 17.99
  • Price/Book 7.53

Options Overview Details

View History
  • Implied Volatility 29.03% (+1.11%)
  • Historical Volatility 26.03%
  • IV Percentile 99%
  • IV Rank 95.06%
  • IV High 29.89% on 03/27/26
  • IV Low 12.42% on 07/24/25
  • Expected Move (DTE 7) 6.17 (2.35%)
  • Put/Call Vol Ratio 1.52
  • Today's Volume 49,152
  • Volume Avg (30-Day) 28,458
  • Put/Call OI Ratio 0.95
  • Today's Open Interest 375,667
  • Open Int (30-Day) 365,067
  • Expected Range 256.87 to 269.21

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $2.83
  • Number of Estimates 7
  • High Estimate $2.88
  • Low Estimate $2.69
  • Prior Year $2.77
  • Growth Rate Est. (year over year) +2.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
222.00 +18.49%
on 06/03/26
263.10 -0.02%
on 07/02/26
+40.15 (+18.01%)
since 06/02/26
3-Month
220.37 +19.36%
on 05/11/26
263.10 -0.02%
on 07/02/26
+20.00 (+8.23%)
since 04/02/26
52-Week
154.21 +70.57%
on 07/08/25
263.10 -0.02%
on 07/02/26
+107.48 (+69.09%)
since 07/02/25

Most Recent Stories

More News
These 3 Dividend Stocks Could Boost Your Income This July

Realty Income, Johnson & Johnson, and Chevron offer yields ranging from 2.2% to 5.1% in July 2026, supported by analyst buy ratings and institutional accumulation.

CVX : 169.20 (+2.12%)
JNJ : 263.04 (+3.57%)
O : 63.84 (+3.27%)
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity

EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:DFTX),(NASDAQ:CMPS),(NASDAQ:GHRS),(NYSE:JNJ) EQNX::TICKER_END

HELP : 6.24 (-0.64%)
CMPS : 13.62 (+2.48%)
GHRS : 27.01 (+2.23%)
JNJ : 263.04 (+3.57%)
DFTX : 44.19 (+1.82%)
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity

NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The way Major Depressive Disorder (MDD) is treated is changing faster than it has in years. For decades, most patients...

HELP : 6.24 (-0.64%)
CMPS : 13.62 (+2.48%)
GHRS : 27.01 (+2.23%)
JNJ : 263.04 (+3.57%)
DFTX : 44.19 (+1.82%)
Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

GENEVA , June 26, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight...

JNJ : 263.04 (+3.57%)
Blackberry Stock Just Scored a New 'Buy' Rating. Here's Why.

Blackberry stock rallies as Stifel announces a bullish $12 price target. Here’s why the investment firm recommends owning BB shares at current levels.

BB : 11.51 (-10.15%)
NVDA : 194.83 (-1.39%)
QCOM : 176.25 (-3.12%)
JNJ : 263.04 (+3.57%)
AMD : 517.82 (-4.26%)
Johnson & Johnson Earnings Preview: What to Expect

Johnson & Johnson is scheduled to report its second-quarter results next month, and analysts expect a single-digit earnings rise.

XLV : 163.74 (+2.63%)
$SPX : 7,483.24 (unch)
JNJ : 263.04 (+3.57%)
The $11 Billion Reason Abbvie Stock Is Up Today

AbbVie stock rallied today on the $10.9 billion acquisition of Apogee Therapeutics. Here’s how you should play ABBV shares at current levels.

APGE : 132.91 (+0.11%)
JNJ : 263.04 (+3.57%)
LLY : 1,213.91 (+1.86%)
ABBV : 261.07 (+3.99%)
REGN : 654.27 (+4.73%)
SNY : 43.16 (+3.68%)
3 Best ETFs to Kick Volatility to the Curb

Low- and minimum-volatility ETFs can help investors fade turbulence in the markets while still participating in upside.

SPLV : 76.73 (+1.98%)
VFMV : 140.96 (+0.81%)
KO : 84.14 (+3.51%)
JNJ : 263.04 (+3.57%)
CNQ : 39.64 (+1.85%)
LVHI : 41.05 (+1.61%)
RIO : 94.42 (+1.15%)
SHEL : 78.02 (+1.89%)
DUK : 129.60 (+3.05%)
FE : 48.53 (+3.10%)
How to Hunt for Mega-Cap Value After the SpaceX IPO

I'm not buying into SpaceX following the record-setting IPO. But I am looking for big value elsewhere. Here's how I start my search.

GOOG : 356.18 (-0.48%)
GOOGL : 359.91 (-0.36%)
SPCX : 162.00 (+2.83%)
$SPX : 7,483.24 (unch)
BRK.A : 761,580.00 (+1.41%)
JPM : 334.47 (+0.12%)
BRK.B : 507.78 (+1.61%)
JNJ : 263.04 (+3.57%)
TOPT : 32.68 (-0.49%)
$IUXX : 29,329.21 (unch)
AMZN : 242.67 (+0.40%)
3 Stocks Doing the Heavy Lifting in Healthcare’s Rebound

Led by Eli Lilly’s GLP-1 success, Humana’s expanding margins, and DexCom’s medtech growth, the healthcare sector is staging a major market rebound.

HUM : 396.75 (-3.09%)
JNJ : 263.04 (+3.57%)
LLY : 1,213.91 (+1.86%)
DXCM : 71.25 (+3.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 275.19
2nd Resistance Point 269.15
1st Resistance Point 266.09
Last Price 263.04
1st Support Level 256.99
2nd Support Level 250.95
3rd Support Level 247.89

See More

52-Week High 263.10
Last Price 263.04
Fibonacci 61.8% 221.50
Fibonacci 50% 208.65
Fibonacci 38.2% 195.81
52-Week Low 154.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.